Monday, June 29, 2015 8:46:23 PM
>>How do you know the disease doesn't typically recur in the third year in this patient population?
I don’t know. What I do know is, based on the cited ADXS anal cancer drug efficacy, the respected Radiation Therapy Oncology Group (RTOG) has agreed to run a pivotal Phase 2/3 anal cancer trial in collaboration with Advaxis. Also, I trust that ADXS management isn’t just hyping their stock by highlighting their anal cancer results. Of course, it’s possible I’m being naive.
I don’t know. What I do know is, based on the cited ADXS anal cancer drug efficacy, the respected Radiation Therapy Oncology Group (RTOG) has agreed to run a pivotal Phase 2/3 anal cancer trial in collaboration with Advaxis. Also, I trust that ADXS management isn’t just hyping their stock by highlighting their anal cancer results. Of course, it’s possible I’m being naive.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
